Interactions of the stereoisomers of α-hydroxytamoxifen with human hydroxysteroid sulfotransferase SULT2A1 and rat hydroxysteroid sulfotransferase STa

Drug Metabolism and Disposition

Volumn 32, Issue 12, 2004, Pages 1501-1508

  Apak, T Idil ^a   Duffel, Michael W ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYTAMOXIFEN; ANTIESTROGEN; DRUG METABOLITE; HYDROXYSTEROID SULFOTRANSFERASE; HYDROXYSTEROID SULFOTRANSFERASE STA; HYDROXYSTEROID SULFOTRANSFERASE SULT2A1; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CATALYSIS; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SULFATION; ENANTIOMER; ENDOMETRIUM CANCER; ENZYME SUBSTRATE; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; STEREOISOMERISM;

ANIMALS; CHROMATOGRAPHY, THIN LAYER; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; RATS; SPECIES SPECIFICITY; STEREOISOMERISM; SULFOTRANSFERASES; TAMOXIFEN;

EID: 9444291414     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.104.000919     Document Type: Article

References (55)

1. Assikis VJ, Neven P, Jordan VC, and Vergote I (1996) A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer 32A:1464-1476.
2. Banoglu E and Duffel MW (1997) Studies on the interactions of chiral secondary alcohols with rat hydroxysteroid sulfotransferase STa. Drug Metab Dispos 25:1304-1310.
3. Banoglu E and Duffel MW (1999) Importance of peri-interactions on the stereospecificity of rat hydroxysteroid sulfotransferase STa with 1-arylethanols. Chem Res Toxicol 12:278-285.
4. Bensadoun A and Weinstein D (1976) Assay of proteins in the presence of interfering materials. Anal Biochem 70:241-250.
5. Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, Perlman JA, and Ford L (1999) Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662.
6. Blanchard RL, Freimuth RR, Buck J, Weinshilboum RM, and Coughtrie MW (2004) A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics 14:199-211.
7. Boocock DJ, Maggs JL, Brown K, White INH, and Park BK (2000) Major inter-species differences in the rates of O-sulphonation and O-glucuronylation of alpha-hydroxytamoxifen in vitro: a metabolic disparity protecting human liver from the formation of tamoxifen-DNA adducts. Carcinogenesis 21:1851-1858.
8. Carmichael PL, Ugwumadu AHN, Neven P, Hewer AJ, Poon GK, and Phillips DH (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475-1479.
9. Chang HJ, Zhou M, and Lin SX (2001) Human dehydroepiandrosterone sulfotransferase: purification and characterization of a recombinant protein. J Steroid Biochem Mol Biol 77:159-165.
10. Chen G, Yin S, Maiti S, and Shao X (2002) 4-Hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol 16:279-285.
11. Crewe HK, Notley LM, Wunsch RM, Lennard MS, and Gillam EMJ (2002) Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4′-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos 30:869-874.
12. Dasaradhi L and Shibutani S (1997) Identification of tamoxifen-DNA adducts formed by alpha-sulfate tamoxifen and alpha-acetoxy tamoxifen. Chem Res Toxicol 10:189-196.
13. Davis W, Venitt S, and Phillips DH (1998) The metabolic activation of tamoxifen and alpha-hydroxytamoxifen to DNA-binding species in rat hepatocytes proceeds via sulphation. Carcinogenesis 19:861-866.
14. Duffel MW, Binder TP, and Rao SI (1989) Assay of purified aryl sulfotransferase suitable for reactions yielding unstable sulfuric acid esters. Anal Biochem 183:320-324.
15. Falany CN, Comer KA, Dooley TP, and Glatt H (1995) Human dehydroepiandrosterone sulfotransferase. Ann NY Acad Sci 774:59-72.
16. Fan PW and Bolton JL (2001) Bioactivation of tamoxifen to metabolite E quinone methide: reaction with glutathione and DNA. Drug Metab Dispos 29:891-896.
17. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, and Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Nat Cancer Inst 86:527-537.
18. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
19. Foster AB, Jarman M, Leung O-T, McCague R, Leclercq G, and Devleeschouwer N (1985) Hydroxy derivatives of tamoxifen. J Med Chem 28:1491-1497.
20. Glatt H, Davis W, Meinl W, Hermersdorfer H, Venitt S, and Phillips DH (1998) Rat, but not human, sulfotransferase activates a tamoxifen metabolite to produce DNA adducts and gene mutations in bacteria and mammalian cells in culture. Carcinogenesis 19:1709-1713.
21. Glatt H, Pauly K, Czich A, Falany JL, and Falany CN (1995) Activation of benzylic alcohols to mutagens by rat and human sulfotransferases expressed in Escherichia coli. Eur J Pharmacol 293:173-181.
22. Hardcastle IR, Horton MN, Osborne MR, Hewer A, Jarman M, and Phillips DH (1998) Synthesis and DNA reactivity of alpha-hydroxylated metabolites of nonsteroidal antiestrogens. Chem Res Toxicol 11:369-374.
23. Jordan VC (2003a) Tamoxifen: a most unlikely pioneering medicine. Nature Rev 2:205-213.
24. Jordan VC (2003b) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46:883-908.
25. Jordan VC (2003c) Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 46:1081-1111.
26. Kupfer D and Dehal S (1996) Tamoxifen metabolism by microsomal cytochrome P450 and flavin-containing monooxygenase. Methods Enzymol 272:152-162.
27. Kuramochi H (1996) Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J Med Chem 39:2877-2886.
28. Liu X, Pisha E, Tonetti DA, Yao D, Li Y, Yao J, Burdette JE, and Bolton JL (2003) Antiestrogenic and DNA damaging effects induced by tamoxifen and toremifene metabolites. Chem Res Toxicol 16:832-837.
29. Lyon ES and Jakoby WB (1980) The identity of alcohol sulfotransferases with hydroxysteroid sulfotransferases. Arch Biochem Biophys 202:474-481.
30. Mani C, Hodgson E, and Kupfer D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab Dispos 21:657-661.
31. Miller JA, Surh Y-J, Liem A, and Miller EC (1990) Electrophilic sulfuric acid ester metabolites of hydroxy-methyl aromatic hydrocarbons as precursors of hepatic benzylic DNA adducts in vivo, in Biological Reactive Intermediates IV (Witmer CM ed), pp 555-567, Plenum Press, New York.
32. Nagata K and Yamazoe Y (2000) Pharmacogenetics of sulfotransferase. Ann Rev Pharmacol Toxicol 40:159-176.
33. Negishi M, Pedersen LG, Petrotchenko E, Shevtsov S, Gorokhov A, Kakuta Y, and Pedersen LC (2001) Structure and function of sulfotransferases. Arch Biochem Biophys 390:149-157.
34. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, and Watabe T (2002) Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 63:1817-1830.
35. Notley LM, de Wolf CJF, Wunsch RM, Lancaster RG, and Gillam EMJ (2002) Bioactivation of tamoxifen by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 15:614-622.
36. Ogura K, Sohtome T, Sugiyama A, Okuda H, Hiratsuka A, and Watabe T (1990) Rat liver cytosolic hydroxysteroid sulfotransferase (sulfotransferase a) catalyzing the formation of reactive sulfate esters from carcinogenic polycyclic hydroxymethylarenes. Mol Pharmacol 37:848-854.
37. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pilot HC, et al. (1998) Effects of antiestrogens tamoxifen, toremifene and ICI 182,780 in endometrial cancer growth. J Natl Cancer Inst 90:1552-1558.
38. Osborne MR, Hewer A, and Phillips DH (2001) Resolution of alpha-hydroxytamoxifen: R-isomer forms more DNA adducts in rat liver cells. Chem Res Toxicol 14:888-893.
39. Phillips DH, Carmichael PL, Hewer A, Cole KJ, and Poon GK (1994) Alpha-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 54:5518-5522.
40. Poon GK, Chui YC, McCague R, Lonning PE, Feng R, Rowlands MG, and Jarman M (1993) Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients. Drug Metab Dispos 21:1119-1124.
41. Potter GA, McCague R, and Jarman M (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 15:439-442.
42. Randerath K, Bi J, Mabon N, Sriram P, and Moorthy B (1994) Strong intensification of mouse hepatic tamoxifen-DNA adduct formation by pretreatment with the sulfotransferase inhibitor and ubiquitous environmental pollutant pentachlorophenol. Carcinogenesis 15:797-800.
43. Sekura R (1981) Adenosine 3′-phosphate 5′-phosphosulfate. Methods Enzymol 77:413-415.
44. Sheng JJ and Duffel MW (2001) Bacterial expression, purification and characterization of rat hydroxysteroid sulfotransferase STa. Protein Expression Purif 21:235-242.
45. Sheng JJ and Duffel MW (2003) Enantioselectivity of human hydroxysteroid sulfotransferase ST2A3 with naphthyl-1-ethanols. Drug Metab Dispos 31:697-700.
46. Sheng JJ, Sharma V, and Duffel MW (2001) Measurement of aryl and alcohol sulfotransferase activity, in Current Protocols in Toxicology (Maines M, Costa LG, Hodgson E, Reed DJ, and Sipes IG eds), pp. 4.5.1-4.5.9, John Wiley & Sons, Inc., New York.
47. Shibutani S, Dasaradhi L, Terashima I, Banoglu E, and Duffel MW (1998a) Alpha-hydroxytamoxifen is a substrate of hydroxysteroid (alcohol) sulfotransferase, resulting in tamoxifen DNA adducts. Cancer Res 58:647-653.
48. Shibutani S, Shaw PM, Suzuki N, Dasaradhi L, Duffel MW, and Terashima I (1998b) Sulfation of alpha-hydroxytamoxifen catalyzed by human hydroxysteroid sulfotransferase results in tamoxifen-DNA adducts. Carcinogenesis 19:2007-2011.
49. Shibutani S, Suzuki N, Terashima I, Sugarman SM, Grollman AP, and Pearl ML (1999) Tamoxifen-DNA adducts detected in the endometrium of women treated with tamoxifen. Chem Res Toxicol 12:646-653.
50. Smith LL, Brown K, Carthew P, Lim CK, Martin EA, Styles J, and White INH (2000) Chemoprevention of breast cancer by tamoxifen: risks and opportunities. Crit Rev Toxicol 30:571-594.
51. Surh YJ (1998) Bioactivation of benzylic and allylic alcohols via sulfo-conjugation. Chem Biol Interact 109:221-235.
52. 2-deoxyguanosinyl)tamoxifen lesions, the major DNA adducts detected in endometrial tissues of patients treated with tamoxifen. Cancer Res 59:2091-2095.
53. White INH (1999) The tamoxifen dilemma. Carcinogenesis 20:1153-1160.
54. Williams G and Iatropoulos M (1993) The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis 14:315-317.
55. Yoshinari K, Petrotchenko EV, Pedersen LC, and Negishi M (2001) Crystal structure-based studies of cytosolic sulfotransferase. J Biochem Mol Toxicol 15:67-75.